# Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)

Study · id `cardio:ct-nct05650411` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05650411](<https://clinicaltrials.gov/study/NCT05650411>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05650411

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 828 participants.

## Technical summary

Registry record NCT05650411. Randomized; single masking; primary purpose treatment. Start 2026-04-26 (actual); primary completion 2028-05-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 828 participants (planned count; ClinicalTrials.gov record NCT05650411, source copy `cardio:ctgov-nct05650411-2026-05-04`, retrieved 2026-10-26)
- Started: 2026-04-26 (actual) (ClinicalTrials.gov record NCT05650411, source copy `cardio:ctgov-nct05650411-2026-05-04`, retrieved 2026-10-26)
- Primary completion: 2028-05-01 (anticipated) (ClinicalTrials.gov record NCT05650411, source copy `cardio:ctgov-nct05650411-2026-05-04`, retrieved 2026-10-26)
- Completion: 2032-05-01 (anticipated) (ClinicalTrials.gov record NCT05650411, source copy `cardio:ctgov-nct05650411-2026-05-04`, retrieved 2026-10-26)
- Countries: Switzerland (ClinicalTrials.gov record NCT05650411, source copy `cardio:ctgov-nct05650411-2026-05-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05650411-2026-05-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)
- Acronym: ULTIMATE-LM
- Condition: Left Main Coronary Artery Stenosis
- Intervention (Device): LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
- Intervention (Drug): P2Y12 inhibitor-based SAPT after short DAPT
- Intervention (Drug): Conventional DAPT
- Lead sponsor: IGLESIAS Juan Fernando
- Lead sponsor class: OTHER
- Collaborator: University of Bern
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: University of Bern (`cardio:org-university-of-bern`)

## Provenance

Content hash: 9b59d563def3daf44bcb8e56fb75e4f9123c1b20cce911a0783245f88be9690a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
